SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA

1SXP · XETRA · Healthcare / Medical Instruments & Supplies

24.55EUR+0.05 (+0.20%)

Price History

Full chart

Market Stats

Previous Close24.5
Open24.6
Day Range23.85 – 24.75
52-Week Range12.62 – 25.6
Volume64.40K
Market Cap3.67B
P/E (TTM)27.06
Forward P/E21.64
EPS0.9
Dividend Yield0.72%
Beta0.99
50-Day Avg22.82
200-Day Avg17.45

About

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Christian Mias
  • Employees5.00K
  • HeadquartersHattenbergstrasse 10, Mainz, Germany, 55122, Germany
  • Websitehttps://www.schott-pharma.com

Leadership

  • Mr. Christian MiasChief Executive Officer · b. 1974
  • Mr. Reinhard Josef MayerCFO & Member of Management Board of SCHOTT Pharma Management AG · b. 1967
  • Mr. Tobias ErfurthHead of Investor Relations
  • Isabelle JeangoudouxHead of Global Product Management
  • Dr. Arne KlokeHead of Service & Sustainability Management

Financials

Income Statement

Line item2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue584.23M648.67M821.14M898.60M957.09M986.21M
Cost of Revenue388.22M422.50M524.72M582.11M634.48M653.75M
Gross Profit196.01M226.17M296.43M316.49M322.61M332.46M
Operating Income91.61M115.25M169.34M170.92M189.96M186.97M
EBITDA--216.33M244.90M262.44M287.21M
Net Income77.48M100.75M125.38M151.84M149.69M146.45M
R&D23.58M22.29M23.53M26.82M24.25M27.92M
Interest Expense1.92M1.67M2.69M7.25M13.49M20.01M

Balance Sheet

Line item2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets596.02M739.89M1.20B1.23B1.44B1.60B
Total Liabilities280.36M320.48M487.46M539.65M650.00M704.90M
Total Equity314.52M417.96M707.28M690.43M790.41M891.78M
Cash18.61M27.86M28.80M24.36M23.18M22.47M

Cash Flow

Line item2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow104.40M132.21M182.12M181.65M224.77M179.92M
Capital Expenditure85.31M98.63M152.69M175.52M145.30M144.76M
Free Cash Flow19.09M33.59M29.43M6.13M79.47M35.16M
Dividends Paid44.04M39.82M11.46M18.88M22.59M24.10M

Earnings

Report DateAug 30, 2023Nov 29, 2023Mar 1, 2024Jun 27, 2024Aug 29, 2024Dec 12, 2024Feb 13, 2025May 14, 2025Aug 12, 2025Dec 11, 2025Feb 10, 2026May 12, 2026Aug 11, 2026Dec 10, 2026
EPS Estimate0.200.140.260.210.200.240.190.240.290.240.180.210.260.33
EPS Actual0.200.160.290.170.310.220.190.260.300.220.220.210.26-
Surprise0.35%15.26%11.54%-20.86%55.00%-9.84%0.00%8.33%3.45%-8.33%22.22%0.00%0.00%-
Timing--Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.67B
Enterprise Value3.64B
Trailing P/E27.06
Forward P/E21.64
Price / Sales3.61
Price / Book3.60
EPS0.9
Book Value6.67
Revenue (TTM)1.02B
Gross Profit (TTM)316.90M
EBITDA249.30M
Profit Margin13.40%
Operating Margin17.36%
Return on Equity14.68%
Return on Assets6.49%
Shares Outstanding150.61M
Shares Float34.35M
Beta0.99
Dividend Yield0.72%
Dividend Rate0.18
Payout Ratio19.78%

Dividends

20261×
0.18Feb 4, 2026
20251×
0.16Feb 5, 2025
20241×
0.15Mar 15, 2024